Peter de Haan
Fondateur chez Amarna Therapeutics BV
Profil
Peter de Haan is the founder and Chief Scientific Officer of Amarna Therapeutics BV, which is founded in 2008.
He is currently a Non-Executive Director at Barranco Resources NL.
Postes actifs de Peter de Haan
Sociétés | Poste | Début |
---|---|---|
Barranco Resources NL
Barranco Resources NL Wholesale DistributorsDistribution Services Barranco Resources NL provides mineral exploration services. The firm is also engaged in discovery, evaluation, and development of mineral resources. The company is headquartered in City Beach, Australia. | Directeur/Membre du Conseil | - |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Fondateur | 01/01/2008 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Barranco Resources NL
Barranco Resources NL Wholesale DistributorsDistribution Services Barranco Resources NL provides mineral exploration services. The firm is also engaged in discovery, evaluation, and development of mineral resources. The company is headquartered in City Beach, Australia. | Distribution Services |
Amarna Therapeutics BV
Amarna Therapeutics BV Medical/Nursing ServicesHealth Services Amarna Therapeutics BV operates as a biotechnology company developing SVac viral gene delivery vector platform. The firm has developed a proprietary SuperVero cell line and SVec gene delivery platform for the development of safe and efficient immunotherapies for major indications within the degenerative, inflammatory and autoimmune disease areas. The company was founded by Ben van Leent and Peter de Haan in 2008 and is headquartered in Leiden, the Netherlands. | Health Services |